Vaxart to Present Research on Second-Generation Norovirus Oral Pill Vaccine Candidate at IDWeek 2025

Vaxart, Inc. (OTCQX: VXRT) (“Vaxart”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that it ...

REFILE-FOCUS-Scientists see downsides to top COVID-19 vaccines from Russia, China

High-profile COVID-19 vaccines developed in Russia and China share a potential shortcoming: They are based on a common cold virus that many people have been exposed to, potentially limiting their ...

CORRECTED-EXPLAINER-How common cold viruses are being used in vaccines from Russia, China

The modified common cold viruses behind high-profile COVID-19 vaccine candidates from China's CanSino Biologics and Russia's Gamaleya Institute have been studied for decades, but are still not widely ...

Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025

Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today ...

Coronavirus Vaccine delay

"RNA vaccines and adenovirus-based vaccines (technologies used to develop vaccines against Covid-19) are already in phase two human trials for other infectious diseases like influenza and a different ...